148 Participants Needed

SNP-ACTH Gel for Kidney Disease

Recruiting at 33 trial locations
NK
Overseen ByNancy Klett, MPH
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Cerium Pharmaceuticals, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

Will I have to stop taking my current medications?

The trial protocol suggests that if you have relapsed after certain immunosuppressive therapies, you need to wait a specific period before joining: more than 3 months for glucocorticoids, calcineurin inhibitors, or mycophenolate mofetil; more than 6 months for chlorambucil or cyclophosphamide; and more than 12 months for rituximab. It doesn't specify about other medications, so it's best to discuss with the trial team.

What data supports the effectiveness of the drug Rituximab for kidney disease?

Rituximab has shown effectiveness in reducing proteinuria (excess protein in urine) in patients with primary membranous nephropathy, a type of kidney disease, as demonstrated in well-powered randomized controlled trials. It is considered a valid alternative to other treatments like glucocorticoid-cyclophosphamide, although the optimal dosing and regimen are still being studied.12345

What safety data exists for Rituximab and related treatments in humans?

Rituximab, used for various conditions, is generally considered safe but can have rare serious side effects like infections, low blood cell counts, and reactivation of hepatitis B. Some patients may experience low potassium levels or late-onset side effects like neutropenia (low white blood cell count) and hypogammaglobulinemia (low antibody levels), which increase infection risk.36789

What makes the SNP-ACTH Gel treatment for kidney disease unique compared to other treatments?

The SNP-ACTH Gel treatment is unique because it combines Rituximab, a medication often used for autoimmune diseases and certain cancers, with a gel form of ACTH (adrenocorticotropic hormone), which may offer a novel approach to managing kidney disease by potentially reducing inflammation and modulating the immune system in a targeted manner.1011121314

What is the purpose of this trial?

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.

Eligibility Criteria

This trial is for patients with primary membranous nephropathy, a kidney disease. They should have a life expectancy over 24 months, confirmed diagnosis via biopsy or positive anti PLA2R antibody test if they have Nephrotic Syndrome, and be at high risk of worsening kidney function. Participants must not have had certain treatments recently and cannot have diabetes or sensitivity to porcine proteins.

Inclusion Criteria

You are at high risk for kidney function loss, according to the KDIGO 2021-Glomerular Diseases Guideline.
I had a good response to immune therapy but my condition worsened after stopping it for over a year.
I have been diagnosed with membranous nephropathy and tested positive for anti-PLA2R antibodies.
See 5 more

Exclusion Criteria

I have been diagnosed with secondary membranous nephropathy.
Your blood test showed a big decrease in a specific antibody within the past year.
Other exclusion criteria may apply
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 3a Treatment

Dose finding phase with SNP-ACTH Gel treatment at two different dose levels for 12 months

12 months
Regular assessments at months 2, 3, 4, 5, 6, 9, 12

Phase 3b Treatment

Comparison of SNP-ACTH Gel at optimal dose versus Rituximab over 12 months

12 months
Rituximab administered at month 1 and month 6

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months

Treatment Details

Interventions

  • Rituximab
  • SNP-ACTH (1-39) Gel
Trial Overview The study is testing SNP-ACTH (1-39) Gel against Rituximab in two phases: Phase 3a to find the best dose and Phase 3b to compare their effectiveness after 24 months in treating primary membranous nephropathy.
Participant Groups
4Treatment groups
Experimental Treatment
Active Control
Group I: Phase 3b Cohort 1Experimental Treatment1 Intervention
Dose level to be confirmed once Phase 3a part is completed
Group II: Phase 3a Cohort 2Experimental Treatment1 Intervention
5 mg SNP-ACTH Gel sc injection 3 times per week
Group III: Phase 3a Cohort 1Experimental Treatment1 Intervention
3 mg SNP-ACTH Gel sc injection 3 times per week
Group IV: Phase 3b Cohort 2Active Control1 Intervention
Rituximab arm: Patients randomized to the rituximab arm will receive 1 g IV infusion on T0 (after baseline measures are collected) and day 15. A second course of rituximab 1g IV infusion will be administered 6 months after the first rituximab infusion and an additional 1 g IV infusion 14 days following the first 6-month infusion.

Rituximab is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Rituxan for:
  • Non-Hodgkin's lymphoma
  • Chronic lymphocytic leukemia
  • Rheumatoid arthritis
  • Granulomatosis with polyangiitis
  • Microscopic polyangiitis
🇪🇺
Approved in European Union as MabThera for:
  • Non-Hodgkin's lymphoma
  • Chronic lymphocytic leukemia
  • Rheumatoid arthritis
  • Granulomatosis with polyangiitis
  • Microscopic polyangiitis
🇨🇦
Approved in Canada as Rituxan for:
  • Non-Hodgkin's lymphoma
  • Chronic lymphocytic leukemia
  • Rheumatoid arthritis
  • Granulomatosis with polyangiitis
  • Microscopic polyangiitis

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cerium Pharmaceuticals, Inc.

Lead Sponsor

Trials
1
Recruited
150+

Findings from Research

In a study of 34 patients with primary membranous nephropathy (PMN), low-dose rituximab (375 mg/m2) resulted in a complete response in only 14.7% and a partial response in 29.4% after 12 months, indicating limited efficacy.
The study suggests that higher doses and longer treatment durations may be necessary to improve response rates, as the current low-dose regimen achieved remission in less than half of the patients.
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.Moroni, G., Depetri, F., Del Vecchio, L., et al.[2022]
In a survey of 380 nephrologists in Japan, only 21.8% reported using rituximab (RTX) for primary membranous nephropathy (pMN), compared to 47.6% for minimal change nephrotic syndrome (MCNS), indicating lower adoption of RTX for pMN despite its recommendation as a standard therapy.
The primary reason for withholding RTX in pMN cases was financial difficulties, with 79.3% of nephrologists citing challenges in securing funding for the treatment.
Practice patterns of rituximab for primary membranous nephropathy 2021 in Japan: a web-based survey of board-certified nephrologists.Miyaoka, Y., Kurita, N., Sofue, T., et al.[2023]
Rituximab is primarily indicated for refractory immune thrombocytopenic purpura and is considered the best treatment for cold agglutinin disease, but its long-term benefit-to-risk ratio remains uncertain, especially in relation to splenectomy.
While rituximab shows promise in treating various autoimmune diseases, including Wegener granulomatosis and HCV-associated cryoglobulinemia, there are significant risks of adverse events, particularly infections and severe reactions in certain patient populations, highlighting the need for further clinical trials.
Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks.Sailler, L.[2022]

References

Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. [2022]
Practice patterns of rituximab for primary membranous nephropathy 2021 in Japan: a web-based survey of board-certified nephrologists. [2023]
Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks. [2022]
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. [2022]
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy. [2022]
Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. [2023]
Hypokalemia after rituximab administration in nephrotic syndrome: two case reports. [2023]
Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. [2018]
Rituximab for immunologic renal disease: What the nephrologist needs to know. [2018]
Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity. [2017]
11.United Statespubmed.ncbi.nlm.nih.gov
Investigation of the drug binding properties and cytotoxicity of DNA-capped nanoparticles designed as delivery vehicles for the anticancer agents doxorubicin and actinomycin D. [2013]
Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer. [2022]
Cyclodextrin-Based Nanohydrogels Containing Polyamidoamine Units: A New Dexamethasone Delivery System for Inflammatory Diseases. [2020]
14.United Statespubmed.ncbi.nlm.nih.gov
[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security